A Retrospective Study of Prognostic Factors and Survival of Breast Cancer Patients with Brain Metastesis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-01-01

Study Completion Date

2027-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to to describe the pattern of BM in breast cancer patients, assess the prognostic significance of patient related-factors and to evaluate the efficacy of various treatment modalities. clinicopathological factors and prognostic factors that affect the occurrence of brain metastases and which factors affect the survival after the occurrence of brain metastases remain to be identified . This may help identify patients at high risk for brain metastases and patients with poor prognosis after brain metastases, thus providing them with some preventive or therapeutic measures.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Breast cancer (BC) has become the malignancy with the highest morbidity rate in women. Despite significant advances in the diagnosis and treatment of breast cancer, metastasis is still an important factor that seriously affects patients' quality of life and prognosis. It has been reported that distant metastases have been found at the initial diagnosis of breast cancer in about 6-10% of patients The bones, lungs, liver and brain are the four most common distant metastatic sites of breast cancer Compared with bone metastases and visceral metastases, patients with brain metastases have significantly worse prognosis The median time from diagnosis of breast cancer to CNS metastasis has been reported to be 33 month The survival of these patients may be affected by factors including molecular subtypes, performance status, ressectability of BM and visceral metastasis burden. When detected, its treatment is usually difficult and unfortunately has reverse effects on life expectancy Multi-disciplinary therapy (MDT) is the first choice for the treatment of brain metastases in breast cancer MDT for breast cancer brain metastasis includes surgery, whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), chemotherapy, endocrine therapy, targeted therapy, etc. For patients with multiple brain metastases and neurological symptoms, WBRT combined with palliative care is the preferred option In general, patients with brain metastases of 3 or less were recommended to receive surgical resection. Patients with 4 to 5 brain metastases but less 3cm in diameter can undergo SRS .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

prognostic factors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

breast cancer

breast cancer patients with -Radiological documentation of BM by computed tomography (CT) OR magnetic resonance imaging (MRI)

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* -Age \>18
* Histological proven breast cancer
* Radiological documentation of BM by computed tomography (CT) OR magnetic resonance imaging (MRI)
* Patients who had been followed up for at least 6 months.

Exclusion Criteria

* -Not histologically proven Breast cancer
* Patient without full medical data
* Those with previous or concurrent diagnosis of second primary malignancy
* Patients with leptomeningeal or dural metastases without co-existent parenchymal metastatic lesions

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Huda Abdelsamee Thabet Mohamed

resident doctor at Clinical oncology department

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Huda Thabet Mohamed, resident doctor

Role: CONTACT

Phone: +201152476153

Email: [email protected]

References

Explore related publications, articles, or registry entries linked to this study.

Yamamoto M, Serizawa T, Higuchi Y, Sato Y, Kawagishi J, Yamanaka K, Shuto T, Akabane A, Jokura H, Yomo S, Nagano O, Aoyama H. A Multi-institutional Prospective Observational Study of Stereotactic Radiosurgery for Patients With Multiple Brain Metastases (JLGK0901 Study Update): Irradiation-related Complications and Long-term Maintenance of Mini-Mental State Examination Scores. Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):31-40. doi: 10.1016/j.ijrobp.2017.04.037. Epub 2017 Aug 7.

Reference Type BACKGROUND

PMID: 28816158 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

prognostic factors+survival BC

Identifier Type: -

Identifier Source: org_study_id